FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DERANGEWANDTEN FORSCHUNG E.V.
发明人:
Antje PRASSE
申请号：
US16478459
公开号：
US20190365744A1
申请日:
2018.01.16
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A pharmaceutical composition or kit has at least one CXCR4 inhibitor and a multi-tyrosine kinase inhibitor. The composition has at least one CXCR4 inhibitor for use in the treatment of cancer or idiopathic pulmonary fibrosis in a subject suffering from the cancer or idiopathic pulmonary fibrosis and receiving a multi-tyrosine kinase inhibitor therapy. A method for identifying whether a subject suffering from cancer or idiopathic pulmonary fibrosis and receiving a multi-tyrosine kinase inhibitor therapy is susceptible to a CXCR4 inhibitor therapy by determining a CXCR4 signal intensity in a PET dataset obtained from the subject, comparing the CXCR signal intensity to a reference, and identifying whether the subject is susceptible based on the results of the comparison.
